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Abstract
 
Murine splenic dendritic cells (DCs) can be divided into two subsets based on CD8
 
 
 
 expression,
but the specific role of each subset in stimulation of T cells is largely unknown. An important
function of DCs is the ability to take up exogenous antigens and cross-present them in the con-
text of major histocompatibility complex (MHC) class I molecules to CD8
 
 
 
 T cells. We previ-
ously demonstrated that, when cell-associated ovalbumin (OVA) is injected into mice, only the
CD8
 
 
 
 DC subset cross-presents OVA in the context of MHC class I. In contrast to this selec-
tivity with cell-associated antigen, we show here that both DC subsets isolated from mice in-
jected with OVA/anti-OVA immune complexes (OVA-IC) cross-present OVA to CD8
 
 
 
 T
cells. The use of immunoglobulin G Fc receptor (Fc
 
 
 
R) common 
 
 
 
-chain–deficient mice re-
 
vealed that the cross-presentation by CD8
 
 
 
 DCs depended on the expression of 
 
 
 
-chain–con-
taining activating Fc
 
 
 
Rs, whereas cross-presentation by CD8
 
 
 
 DCs was not reduced in 
 
 
 
-chain–
 
deficient mice. These results suggest that although CD8
 
 
 
 DCs constitutively cross-present
exogenous antigens in the context of MHC class I molecules, CD8
 
 
 
 DCs only do so after acti-
vation, such as via ligation of Fc
 
 
 
Rs. Cross-presentation of immune complexes may play an
important role in autoimmune diseases and the therapeutic effect of antitumor antibodies.
Key words: antigen presentation • cytotoxic T lymphocyte • cross-priming • dendritic cell • 
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Introduction
 
Dendritic cells (DCs)
 
*
 
 have the capacity to take up, pro-
cess, and present exogenous antigens in association with
MHC class I molecules (1). This pathway is termed cross-
presentation and the resulting CD8
 
 
 
 T cell priming is re-
ferred to as cross-priming. It was first noted when mice
primed with cells that expressed foreign minor histocom-
patibility antigens but not host MHC molecules, generated
minor antigen specific, host MHC-restricted CD8
 
 
 
 T cells
(2, 3). This indicated that host APCs had taken up the ex-
ogenous cell-associated minor histocompatibility antigens
and presented them in the context of their own MHC class
I molecules. As cross-presentation allows animals to mount
CD8
 
 
 
 T cell responses to antigens not expressed by the
APCs, this pathway is essential for many immune responses
to viral, bacterial, and tumor antigens (4–8).
Murine splenic DCs can be divided into two subsets on
the basis of CD8
 
 
 
 expression. CD8
 
 
 
 DCs have high
CD11b expression and can be further subdivided into a
CD4
 
 
 
 and a CD4
 
 
 
 subset, whereas CD8
 
 
 
 DCs express less
CD11b (9–12). These two subsets of CD8
 
 
 
 and CD8
 
 
 
DCs have also been referred to as myeloid and lymphoid
DCs respectively. The role of these different DC subsets in
the induction of immune responses is not completely un-
derstood. Initially it was suggested that CD8
 
 
 
 DCs were
stimulatory APCs and CD8
 
 
 
 DCs were tolerizing APCs
(13, 14). Later reports indicated a role for CD8
 
 
 
 and CD8
 
 
 
DC subsets in the selective stimulation of Th1 and Th2
cells respectively (15–17). However, recently both DC
subsets have been shown to produce the Th1 stimulatory
cytokine IL-12 and it has been suggested that the DC sub-
types express a different repertoire of pattern recognition
receptors which lead to different immune responses when
engaged (18–22). When we evaluated MHC class I–restricted
cross-presentation of antigen introduced in a cell-associated
form in vivo, we found that antigen was presented only by
the CD8
 
 
 
 DC subset (23). Because both types of DCs
were able to stimulate CD8
 
 
 
 T cells when coated with
peptide, this result suggested that the CD8
 
  
 
DC subset had
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a specialized cross-presentation function that the CD8
 
 
 
DC subset lacked. More evidence for this hypothesis was
provided by a recent study in which cross-presentation of
soluble antigen was evaluated (24).
In vitro studies have shown that antigens complexed
with IgG are much more efficiently cross-presented by
DCs than soluble antigen. This cross-presentation in the
context of MHC class I molecules coincides with activa-
tion of DCs and with presentation of immune complex
antigen in the context of MHC class II molecules (25–27).
Subsequent in vitro studies showed that DCs, but not
macrophages, possess a specialized cross-presentation trans-
port system in which immune complexes are transferred
from the endosome to the cytosol where they become
available for the classical MHC class I antigen processing
pathway (28). For both the activation of DCs by immune
complexes, as well as the cross-presentation of immune
complexes, the common 
 
 
 
-chain of the Fc
 
 
 
 receptors
(Fc
 
 
 
R) was essential (26).
In the mouse, three Fc
 
 
 
Rs exist that can interact with
IgG (for reviews, see references 29 and 30). Fc
 
 
 
RI is a re-
ceptor with high affinity for monomeric IgG2a, whereas
Fc
 
 
 
RII and Fc
 
 
 
RIII have been described to interact pref-
erentially with IgG1, IgG2a, and IgG2b immune com-
plexes. Both Fc
 
 
 
RI and Fc
 
 
 
RIII are multimeric complexes
including the common 
 
 
 
-chain that contains an activating
immune receptor tyrosine activation motif (ITAM). Bind-
ing to Fc
 
 
 
RI and Fc
 
 
 
RIII leads to phagocytosis by macro-
phages, antibody dependent cell-mediated cytotoxity by
NK cells and mast cell degranulation (31). In contrast, mu-
rine Fc
 
 
 
RII consists of one 
 
 
 
 chain that contains an inhib-
itory immune receptor tyrosine inhibition motif (ITIM).
Four isoforms of murine Fc
 
 
 
RII exist and ligation of these
receptors generally results in an inhibitory signal. Interac-
tion of the b1 isoform of Fc
 
 
 
RII on B cells and mast cells
results in inhibitory effects on B cell receptor and Fc
 
 
 
RI-
mediated activation respectively. Myeloid cells express the
b2 isoform of Fc
 
 
 
RII which mediates endocytosis of im-
mune complexes and subsequent antigen presentation (32),
but which also has a down-regulatory action on the activa-
tion status of macrophages (33).
Although in vitro studies have shown expression of all
three Fc
 
 
 
Rs by bone marrow–derived DCs and DC cell
lines, relatively little is known of Fc
 
 
 
R expression on DC
subsets and their role in the uptake and presentation of im-
mune complexes in vivo. In addition to Fc
 
 
 
Rs, comple-
ment receptors may play an important role in cross-presen-
tation of immune complexes in vivo, as DCs express
the complement receptors C3 (CD18/CD11b) and C4
(CD18/CD11c) and possibly also the C1q receptor (34).
We set out to determine the cross-presentation of immune
complexes by splenic CD8
 
 
 
 and CD8
 
 
 
 DC subsets and to
define the role of Fc
 
 
 
Rs in this process.
 
Materials and Methods
 
Mice.
 
C57BL/6 (B6) mice, Fc
 
 
 
RII-deficient mice, Fc
 
 
 
-
chain–deficient mice lacking Fc
 
 
 
RI and Fc
 
 
 
RIII, and Fc
 
 
 
R de-
ficient mice (Fc
 
 
 
RII 
 
 
 
 Fc
 
 
 
-chain–deficient mice) were pur-
chased from Taconic Farms. OT-I/Thy1.1 and OT-I/RAG1-
deficient mice were bred in our specific pathogen free facility and
have a transgenic V
 
 
 
2V
 
 
 
5 TCR specific for the OVA
 
257–264
 
epitope in the context of H2-K
 
b
 
. OT-II mice were a gift from
Dr. A. Rudensky (University of Washington, Seattle, WA) and
have a transgenic V
 
 
 
2V
 
 
 
5 TCR specific for the OVA
 
323–339
 
epitope in the context of I-A
 
b
 
 (35).
 
Antibodies.
 
CD11c-, CD8
 
 
 
-, Fc
 
 
 
RII/III-specific, biotinyl-
ated anti–mouse IgG2a antibodies and mouse IgG2a and IgG2b
were purchased from BD Biosciences. Purified anti-Fc
 
 
 
RII anti-
body (K9.361) was a gift from Dr. U. Hämmerling (Memorial
Sloan-Kettering Cancer Center, New York, NY; references 36–
38). For Fc
 
 
 
RI staining, cells were first incubated with biotinyl-
ated mouse IgG2a followed by a blocking step with nonlabeled
anti-Fc
 
 
 
RII/III antibody containing supernatant with 10 
 
 
 
g/ml
mouse IgG, 10 
 
 
 
g/ml rat IgG, and 10 
 
 
 
g/ml hamster IgG (ICN
Biomedicals). After the blocking step, cells were incubated with
streptavidin-allophycocyanin (APC), CD11c-FITC, and CD8
 
 
 
-
PE. For Fc
 
 
 
RII staining, cells were first incubated with anti-
Fc
 
 
 
RII antibody or isotype control followed by a blocking step.
After the blocking step, cells were incubated with biotinylated
anti–mouse IgG2a antibody followed by streptavidin-APC,
CD11c-FITC, and CD8
 
 
 
-PE. For Fc
 
 
 
RII/III staining cells were
first stained with biotinylated anti-Fc
 
 
 
RII/III antibody or isotype
control. Subsequently, cells were incubated with streptavidin-
APC, CD11c-FITC, and CD8
 
 
 
-PE. Flow cytometry was con-
ducted on a FACSCalibur™ and analyzed using CELLQuest™
software (Becton Dickinson).
 
DC Purification.
 
Spleens from 10–20 mice were cut into
small pieces and digested by stirring at 37
 
 
 
C for 45 min in
RPMI-1640 containing 1 WU/ml Liberase RI (Roche) and 50
 
 
 
g/ml DNase I (Roche). EDTA was added to a final concentra-
tion of 10 mM, and the cell suspension was incubated for an ad-
ditional 10 min at room temperature. RPMI-1640 with 10%
FCS/10 mM EDTA/20 mM Hepes (RP10/HE) was added and
the cells were pelleted. Red blood cells were lysed with ACK ly-
sis buffer. Cells were washed once with RP10/HE and undi-
gested material was removed by filtration through a 100 
 
 
 
m cell
strainer. CD11c
 
 
 
 DCs were purified using anti-CD11c micro-
beads and the autoMACS system (Miltenyi Biotec) according to
manufacturer’s instructions. To purify DC subsets, Fc
 
 
 
RII and
III on CD11c
 
 
 
 DCs were blocked with 2.4G2 for 10 min and
subsequently stained with CD11c-FITC and CD8-PE for 20 min
at 4
 
 
 
C in RP10/HE under continuous rotation. Cells were
washed twice with RP10/HE and resuspended in RPMI with
20% FCS/10 mM EDTA/20 mM Hepes. Cell sorting was per-
formed in HBSS with 25 mM Hepes using a FACS Vantage™
(Becton Dickinson). Autofluorescent cells were gated out using
the FL3 channel and CD8
 
 
 
 and CD8
 
 
 
 CD11c
 
high
 
 DCs were
sorted. After sorting the cells were washed twice in RP10 to re-
move EDTA. The purity of sorted CD8
 
 
 
 and CD8
 
 
 
 DC subsets
was minimally 95%.
 
Generation of OVA Immune Complexes.
 
OVA (Calbiochem)
was dissolved in PBS (3 mg/ml). Rabbit anti-OVA IgG fraction
and rabbit anti-HRP IgG fraction (ICN Biomedicals) were puri-
fied over Protein A columns and diluted in PBS (4 mg/ml). OVA
and anti-OVA antibodies or anti-HRP antibodies were mixed
together at a concentration of 0.38 mg/ml OVA and 1.49 mg/ml
anti-OVA or anti-HRP in PBS and incubated for 30 min at
37
 
 
 
C. This mixture was further diluted in PBS to 0.25 mg/ml
OVA and 1mg/ml anti-OVA or anti-HRP. Mice were primed
with 50 
 
 
 
g OVA/200 
 
 
 
g anti-OVA or anti-HRP in 200 
 
 
 
l by 
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tail vein injection. For uptake of fluorescent OVA-immune com-
plexes, mice were primed with 100 
 
 
 
g DQ OVA (Molecular
Probes) complexed to 400 
 
 
 
g anti-OVA. DQ OVA is a self-
quenched conjugate of ovalbumin that exhibits bright green fluo-
rescence upon proteolytic degradation.
 
Proliferation Assay. To detect OVA presentation, different
DC preparations were used as stimulators for naive RAG1-defi-
cient OT-I cells or OT-II cells in a [3H]thymidine incorporation
assay. In some experiments CD8  T cells or CD4  T cells were
purified from RAG1-deficient OT-I or OT-II spleen and lymph
node cells using anti-CD8 or anti-CD4 microbeads and the au-
toMACS system. Titered numbers of nonirradiated DCs were in-
cubated with 105 OT-I RAG1 /  or OT-II cells in flat bottom
plates in 200  l RP10. As a positive control, stimulator cells were
coated with 1  M OVA257–264 or with 10  M OVA323–339 pep-
tide for 1 h and washed three times. After 48 h, the plates were
pulsed for 16 h with 1  Ci/well of [3H]thymidine and harvested.
Carboxyfluorescein Diacetate Succinimidyl Ester Labeling of OT-I
Cells. Spleen and lymph node cells from OT-I mice were
washed twice in PBS containing 0.1% BSA. To label cells with
the intracellular fluorescent dye carboxyfluorescein diacetate suc-
cinimidyl ester (CFSE; Molecular Probes) the cells were resus-
pended at 5   107 cells/ml in PBS, 0.1% BSA with 10  M CFSE
for 10 min at 37 C. Cells were washed twice with cold RP10
followed by two washes in PBS. 4   106 CD8 Va2  CFSE 
OT-I cells in 200  l of PBS were injected into the tail vein.
Results
In Vivo Processing and Presentation of Immune Complexes by
DCs. Previous in vitro studies have shown that immune
complexes are much more efficiently taken up by DCs and
cross-presented to T cells than soluble antigens (26, 27). To
determine whether this enhancement also occurs in vivo,
we injected B6 mice with 50  g soluble OVA alone, OVA
coincubated with a control anti-HRP IgG antibody, or
OVA coincubated with anti-OVA IgG antibody (OVA-
IC). 14 h after injection CD11c  DCs were isolated from
spleens and used as stimulators for naive MHC class
I–restricted OVA-specific TCR transgenic OT-I, and MHC
class II restricted OVA-specific TCR transgenic OT-II T
cells in an in vitro proliferation assay. As shown by the data
in Fig. 1, DCs from mice injected with soluble OVA alone
or together with the irrelevant antibody were not able to
stimulate T cells. In contrast, injection of OVA-IC resulted
in strong proliferation of OT-I and OT-II T cells, indicat-
ing an efficient uptake and presentation of OVA-IC by
DCs in vivo.
Cross-presentation of immune complexes by DCs in
vitro has been shown to involve an endosome-to-cytosol
transport (26, 28). In the cytosol the antigens follow the
‘classical’ MHC class I antigen processing pathway in
which the antigens are processed by the proteasome and
transported into the ER by the transporter associated with
antigen processing (TAP) transporter. In the ER the anti-
gens subsequently bind to nascent MHC class I molecules.
Evidence for another MHC class I cross-presentation path-
way suggests that peptides can bind to recycled MHC class
I molecules that are present in the endosomal–lysosomal
compartments and this does not require the presence of a
TAP transporter. To investigate which pathway is used by
in vivo primed DCs, we injected TAP-deficient mice with
OVA-IC. TAP-deficient DCs lacked MHC class I–restricted
OVA presentation, whereas MHC class II–restricted
presentation of immune complexes remained intact (un-
published data). This indicates that DCs transport OVA-
IC antigens from the endosome to the cytosol in vivo,
where they follow the ‘classical’ MHC class I processing
pathway.
Expression of Fc Rs by DC Subsets. Uptake of immune
complexes by DCs can be mediated by Fc Rs or by com-
plement receptors. A major role for Fc Rs was implicated
by in vitro studies concerning cross-presentation by DCs
and by in vivo studies on inflammatory responses induced
by immune complexes (26, 39, 40). However, the expres-
sion of activating and inhibitory Fc Rs on the CD8  and
CD8  DC subsets was unknown. Because the relative ratio
of these receptors may be of importance for the effect of
immune complexes, we set out to determine the expres-
sion of the three Fc Rs on DC subsets.
As Fc RI is the only receptor capable of binding mono-
meric mouse IgG2a, we determined functional Fc RI ex-
Figure 1. DCs present OVA epitopes in association with both MHC
class I and II after in vivo injection of OVA-IC. B6 mice were primed
with 50  g soluble OVA, 50  g OVA incubated with 200  g anti-HRP
antibodies, or 50  g OVA with 200  g anti-OVA antibodies (OVA-IC).
CD11c  DCs were isolated 14 h after injection and analyzed for their
ability to stimulate T cells in vitro. The indicated numbers of DCs were
coincubated with RAG1-deficient OT-I cells (A) or purified CD4  OT-II
cells (B). Proliferation of cells was determined by [3H]thymidine incorpo-
ration. Error bars indicate SEM of triplicate wells.820 Cross-Presentation of Immune Complexes by Dendritic Cell Subsets
pression using biotinylated mouse IgG2a. We observed
strong binding of mouse IgG2a to splenic autofluorescent
cells (AFCs) that are mostly macrophages (unpublished
data; reference 10). In contrast, much lower levels of bind-
ing to both DC subsets was observed (Fig. 2 A). This sug-
gests that the CD8  and CD8  DC subsets have low ex-
pression of Fc RI. RT-PCR analysis of sorted CD8  and
CD8  DC subsets also showed very low message for the
Fc RI  chain (unpublished data).
Next we analyzed the expression of Fc RII by using the
Ly-17.2 antibody K9.361 (Fig. 2 B) (36–38). Both the
CD8  and the CD8  DC subsets showed clear staining
with this antibody, although the staining of CD8  DCs was
lower and more heterogenous than that of CD8  DCs.
This indicates that both subsets express Fc RII. Using the
2.4G2 antibody we analyzed the expression of Fc RII and
Fc RIII on the DC subsets (Fig. 2 C). CD8  DCs from
B6 mice expressed high levels of Fc RII/III, whereas
CD8  DCs showed lower, but clear expression of Fc RII/
III (Fig. 2 C). To analyze the expression of Fc RIII, we
purified CD11c  DCs from mice deficient in Fc RII.
CD8  and CD8  DC subsets from mice that lacked Fc-
 RII showed staining with 2.4G2 indicating the presence
of Fc RIII. DCs from mice deficient in all three Fc Rs
did not stain with 2.4G2 (Fig. 2 C). Both the CD8  and
CD8  DC subsets from Fc RII-deficient mice exhibited
significantly lower staining with 2.4G2 compared with
wild-type DC subsets. This indicates that Fc RII is more
highly expressed than Fc RIII on both CD8  and CD8 
DC subsets from normal mice.
In conclusion, both DC subsets express low levels Fc RI
and significant levels of Fc RII and Fc RIII. The level of
expression of both Fc RII and Fc RIII appears to be
higher on CD8  DC than on CD8  DCs, but this may
partly be explained by differences in cell size as CD8  DCs
are larger than CD8  DCs. However, the two DC subsets
do not appear to differ substantially in the relative ratio of
expression of the activating and inhibitory Fc Rs as both
express higher levels of Fc RII compared with Fc RIII.
Therefore, the CD8  and CD8  DC subsets are not likely
to receive substantially different activating and/or inhibi-
tory signals after immune complex–Fc R interaction.
Presentation of Immune Complexes by CD8  and CD8 
DC Subsets. Both cell-associated and soluble antigens are
preferentially cross-presented by CD8  DCs (23, 24). To
determine the cross-presentation of immune complexes by
DC subsets, we purified CD8  and CD8  DC subsets
from mice that had been injected with OVA-IC and used
them as stimulators for OVA specific OT-I and OT-II T
cells. In contrast to cell-associated and soluble antigens,
uptake of immune complexes in vivo lead to strong stimu-
lation of OT-I T cells by both CD8  and CD8  DC sub-
sets (Fig. 3 A).
The two DC subsets did differ in their capacity to stim-
ulate OVA-specific MHC class II–restricted OT-II cells:
CD8  DCs exhibited a substantially lower level of stimu-
lation of OVA specific CD4  T cells compared with
CD8  DCs (Fig. 3 B). This preferential presentation of
OVA-IC by CD8  DCs to CD4  T cells was similar to
that seen with soluble OVA (24). These results suggest that
whereas CD8  DCs transfer OVA-IC to both the MHC
class I and class II presentation pathway, CD8  DCs
mainly transport antigens to the cytosol to be presented in
MHC class I.
Figure 2. Both CD8  and CD8  DCs express Fc-
 RII and RIII. CD11c  DCs were purified from B6
(A–C), and from Fc RII-deficient (Fc RIIko; C), and
mice deficient in all three Fc Rs (Fc Rko; C) and
stained with antibodies specific for CD11c and CD8.
DCs were gated on high expression of CD11c and the
absence or presence of CD8. (A) Fc RI expression was
determined by FACS® analysis of mouse IgG2a bind-
ing to CD8  and CD8  DCs. Bold line depicts mouse
IgG2a binding compared with background staining in
the absence of mouse IgG2a. (B) Fc RII expression on
CD8  and CD8  DCs was determined by staining
with specific anti-Fc RII antibody (bold line) com-
pared with isotype control antibody (fine line). (C)
The histograms show Fc RII/III expression of CD8 
and CD8  DCs from B6 mice (bold line), Fc RIIko
(shaded histogram), and Fc Rko mice (fine line).821 den Haan and Bevan
Cross-Presentation in Fc -Chain and Fc R-deficient Mice.
Fc Rs have been shown to be important in the cross-pre-
sentation of immune complexes, as in vitro–generated DCs
from mice that were deficient in the Fc RI and Fc RIII-
associated  -chain lost their capacity to cross-present anti-
gen in the context of MHC class I (26). In addition, Fc Rs
play an important role in the development of inflammatory
reactions caused by immune-complexes in vivo (for re-
views, see references 29, 30, and 41). To determine
whether DCs from mice that are deficient in the Fc RI
and Fc RIII-associated   -chain loose their capacity to
cross-present immune complexes in vivo, we primed Fc -
chain–deficient mice with OVA-IC and 14 h later isolated
CD11c  DCs to test as stimulators for OT-I and OT-II
cells. CD8  DCs from these mice were still able to activate
OVA-specific OT-I cells, but, strikingly, CD8  DCs lost
their MHC class I restricted cross-presentation capacity
(Fig. 4 A). No effects were seen on the MHC class II re-
stricted OVA presentation by the two DC subsets from the
 -chain–deficient mice compared with wild-type mice
(Figs. 4 B and 3 B). This suggests that, although immune
complexes are still taken up by both DC subsets, the CD8 
DCs lost the capacity to cross-present in the context of
MHC class I molecules.
To determine the role of the inhibitory Fc R in the
cross-presentation of immune complexes, we analyzed
MHC class I–restricted cross-presentation by CD8  and
CD8  DC subsets from Fc RII-deficient mice (unpub-
lished data). In contrast to the loss of cross-presentation by
CD8  DC in Fc  -chain–deficient mice, the absence of in-
hibitory Fc RII did not have a major effect on cross-pre-
sentation by this DC subset. Cross-presentation by CD8 
DCs appeared to be increased twofold in the absence of
Fc RII. This suggests that immune complex interaction
Figure 3. Both CD8  and CD8- DC subsets cross-present OVA-IC in
association with MHC class I molecules, whereas presentation in associa-
tion with MHC class II molecules is mainly restricted to CD8  DCs. B6
mice were injected with OVA-IC and 14 h after injection CD11c  DCs
were isolated. CD8  and CD8  DC subsets were FACS® sorted and ana-
lyzed for their ability to stimulate T cells in vitro. Indicated numbers of
DCs were coincubated with RAG1-deficient OT-I cells (A) or purified
CD4  OT-II cells (B). Proliferation of cells was determined by [3H]thy-
midine incorporation. Error bars indicate SEM of triplicate wells.
Figure 4. Only CD8  and not CD8  DCs from Fc -chain–deficient
mice cross-present OVA-IC to CD8  T cells. Fc -chain–deficient mice
were injected with OVA-IC and 14 h after injection CD11c  DCs were
isolated. CD8  and CD8  DC subsets were FACS® sorted and analyzed
for their ability to stimulate T cells in vitro. Indicated numbers of DCs
were coincubated with purified CD8  RAG1-deficient OT-I cells (A) or
purified CD4  OT-II cells (B). Proliferation of cells was determined by
[3H]thymidine incorporation. Error bars indicate SEM of triplicate wells.822 Cross-Presentation of Immune Complexes by Dendritic Cell Subsets
with Fc RII does not significantly inhibit cross-presenta-
tion in CD8  DCs, but may decrease cross-presentation in
CD8  DCs.
Mice deficient in all three Fc Rs have been generated
by crossing Fc RII-deficient mice with mice deficient in
the common  -chain. To determine whether the uptake of
immune complexes in the absence of activating Fc Rs was
due to interaction with Fc RII, we isolated DC subsets
from mice that were deficient in all three Fc Rs that been
primed with OVA-IC 14 h previously. Similarly to the
 -chain–deficient mice, CD8  DCs from Fc R-deficient
mice were very good stimulators for OT-I cells, whereas
CD8  DCs had a reduced capacity compared with wild-
type mice (Fig. 5 A). The deficit of the CD8  DCs, how-
ever, seemed less complete compared with the  -chain–
deficient mice. Again no drastic effects were observed for
the MHC class II–restricted presentation by the two DC sub-
sets from the Fc R-deficient mice compared with wild-
type mice (Fig. 5 B).
In conclusion, although both DC subsets express the
same set of Fc Rs, in the absence of the two activating
Fc Rs or all three Fc Rs, CD8  DCs specifically loose
their capacity to cross-present OVA-IC to MHC class
I–restricted T cells, whereas the presentation by CD8  DCs
is not affected. In contrast, the pattern of presentation of
OVA-IC to MHC class II–restricted T cells is not changed
by the absence of Fc Rs.
Fc R-deficient DCs Take Up OVA-IC. To investigate
whether the decrease of cross-presentation by CD8  DCs
in the absence of activating Fc Rs could be due to a selec-
tive decrease in uptake of OVA-IC by this subset, we iso-
lated DCs from mice that had been injected with fluores-
cent OVA-IC (Fig. 6). Both CD8  and CD8  DCs
isolated from mice that were deficient in the activating
 -chain and in mice that were deficient for all three Fc Rs
showed similar or even increased uptake of fluorescent
OVA-IC compared with wild-type DCs. This indicates
that Fc Rs are not absolutely required for the uptake of
immune complexes by DCs in vivo and that other recep-
tors expressed on DCs, such as C1q, C3 (CD18/CD11b),
and C4 (CD18/CD11c) complement receptors, may be in-
volved in this process.
This result indicates that the loss of cross-presentation in
the CD8  DC subset in the absence of activating Fc Rs
cannot be explained by decreased uptake of immune com-
plexes. Therefore, signaling through the activating Fc Rs
or changes in intracellular trafficking induced by acti-
vating Fc R interactions must be required for MHC class
I–restricted presentation by CD8  DCs.
In Vivo Proliferation of CD8  T Cells by OVA-IC in Wild-
Type and Fc R-deficient Mice. In the absence of all three
Fc Rs, CD8  DCs exhibited a significantly decreased
ability to cross-present OVA to CD8  T cells, whereas
cross-presentation by the CD8  DCs was unaffected (Fig.
5). To investigate whether the absence of Fc Rs had an
effect on the proliferative response of OVA-specific CD8 
T cells in vivo, we transferred CFSE-labeled OT-I cells
into wild-type mice, into mice that were deficient in
Fc RI and Fc RIII, and into mice that were deficient in
all three Fc Rs. Mice were primed with OVA-IC and 3 d
later we determined the proliferation of OT-I cells in the
spleen. Whereas nonimmunized mice only contained OT-I
cells with CFSE high intensity (Fig. 7 A), all three types
of mice that had received OVA-IC contained much
higher numbers of OT-I cells with much lower CFSE in-
tensity (Fig. 7 B). Comparison of the CFSE levels indi-
cated that the OT-I cells had divided 4–7 times in the
OVA-IC injected hosts, and no difference in the prolifera-
tion of OT-I cells in the absence or presence of Fc R was
observed. This suggests that the transferred OT-I cells
were efficiently activated by CD8  DCs and that MHC
class I–restricted presentation CD8  DCs is redundant in
this process.
Figure 5. CD8  DCs from Fc R-deficient mice have strongly de-
creased capacity to cross-present OVA-IC to CD8  T cells. Fc R-defi-
cient mice were injected with OVA-IC and 14 h after injection CD11c 
DCs were isolated. CD8  and CD8  DC subsets were FACS® sorted and
analyzed for their ability to stimulate T cells in vitro. Indicated numbers
of DCs were coincubated with purified CD8  RAG1-deficient OT-I
cells (A) or purified CD4  OT-II cells (B). Proliferation of cells was de-
termined by [3H]thymidine incorporation. Error bars indicate SEM of
triplicate wells.823 den Haan and Bevan
Discussion
In mouse spleen, DCs can be divided into CD8  and
CD8  subsets and the latter can be further separated into
CD4  and CD4  subsets (9–12). In addition, there is evi-
dence for an IFN  producing plasmacytoid DCs in mouse
spleen (42–44). In mouse lymph nodes, five different DC
subsets have been distinguished (45). Although largely un-
known, it is likely that these different DC subsets have dif-
ferent functions in the initiation of immune responses.
In this study, we investigated the capacity of the CD8 
and CD8  splenic DC subsets to present immune-com-
plexes in the context of MHC class I and II molecules and
the role of Fc Rs in this process. Both CD8  and CD8 
DC subsets were found to have similar Fc R expression:
clear expression of both Fc RII and Fc RIII, but low ex-
pression of Fc RI. Both DC subsets were highly efficient
in the cross-presentation of immune complexes in the con-
text of MHC class I molecules in wild-type mice. Unex-
pectedly, in the absence of activating Fc RI and Fc RIII,
CD8  DCs lost the ability to cross-present immune com-
plexes in the context of MHC class I molecules, whereas
CD8  DCs retained this capacity. This selective cross-pre-
sentation by the CD8  DC subset in the absence of activat-
ing Fc Rs is similar to that seen with the cross-presentation
of cell-associated and soluble antigen (23, 24).
What is the role for activating Fc Rs in the MHC class
I–restricted cross-presentation by CD8- DCs? Fc Rs may
be involved in cross-presentation of immune complexes at
three different levels: they are involved in the uptake of im-
mune complexes, in the intracellular trafficking of immune
complexes, and in transmitting activating or inhibitory sig-
nals to the cell. At all these levels the CD8  DCs could po-
tentially be affected by the absence of activating Fc Rs.
Our data regarding the uptake of immune complexes by
DCs indicate that Fc Rs are not essential for this process in
vivo (Fig. 6) and strongly suggest that other receptors, such
as complement receptors, are involved in this process. Solu-
Figure 6. Both DC subsets from B6
mice, Fc -chain–deficient mice and
Fc R-deficient mice take up OVA-IC
in vivo. CD11c  DCs were isolated
from control mice or mice injected
with fluorescent DQ OVA-IC 14 h
previously. Dot plots depict CD8 ex-
pression and uptake of DQ OVA by
DCs isolated from B6 mice, Fc -chain–
deficient mice and Fc R-deficient
mice. DCs were gated on high CD11c
expression, while autofluorescent cells
were excluded.824 Cross-Presentation of Immune Complexes by Dendritic Cell Subsets
ble immune complexes activate complement and bind to
complement receptor 1 on erythrocytes (41, 46, 47). This
results in removal of immune complexes as erythrocytes
travel to the liver and spleen where the immune complexes
are removed from the erythrocytes by phagocytes. In addi-
tion, binding of complement to antigen has been shown to
increase immunogenicity significantly due to binding to
complement receptor 2 on B cells (48). Although CD8 
and CD8  DC subsets do not express complement receptor
1 or 2, they strongly express complement receptors 3
(CD18/CD11b) and 4 (CD18/CD11c) and these may be
involved in the uptake of immune complexes.
As the uptake of immune complexes is not substantially
decreased in the absence of Fc Rs, do the Fc Rs direct an-
tigen to different processing compartments? In the case of
B cell antigen processing for MHC class II, it has been sug-
gested that antigens taken up by activating Fc Rs may be
targeted to different processing routes than antigens taken
up by Fc RII or other receptors (32). It remains to be
shown whether activating and inhibitory Fc Rs target to
different MHC class I processing pathways in DCs. Fur-
thermore this would not explain why this mechanism
would be essential in only CD8  DCs and not in CD8 
DCs, as cross-presentation by CD8  DCs is not affected in
the absence of activating Fc Rs.
The third known function of  -chain containing Fc Rs
is that these receptors can activate cells via their ITAM mo-
tif. Activation mediated by  -chain containing Fc Rs
could potentially result in changes in the intracellular traf-
ficking and processing of not only Fc R bound antigens,
but also of antigens taken up by other mechanisms (49).
Bone marrow–derived DCs have been shown to gain the
ability to cross-present in the context of MHC class I mol-
ecules and to up-regulate costimulatory molecules after in-
teraction of immune complexes with activating Fc Rs in
vitro (26, 50). As in vivo only a small percentage of the
DCs take up immune complexes, we failed to detect con-
sistent and significant upregulation of costimulatory mole-
cules in vivo. However, these in vitro studies clearly sug-
gest that DCs will also be activated by immune-complexes
in vivo. DC activation may be achieved by the direct inter-
action of immune complexes with the activating Fc Rs.
Alternatively, as Fc Rs have been shown to be the main
regulators of inflammation by immune complexes (for re-
views, see references 29, 30, and 41), DC activation may
occur indirectly via inflammatory mediators. We think that
this FcR -chain–mediated activation of CD8  DCs en-
ables them to cross-present antigens in the context of
MHC class I. The hypothesis that activation of CD8  DCs
is necessary for their ability to cross-present is further sup-
ported by a recent study concerning cross-presentation of
soluble antigen. In this study, CD8  DCs could not cross-
present soluble OVA unless further activated by LPS (24).
In contrast to CD8  DCs, CD8  DCs cross-present im-
mune complexes in the context of MHC class I molecules
regardless of the presence or absence of activating Fc Rs.
CD8  DCs have been shown to be highly efficient in
cross-presenting all types of antigens studied so far, which
include cell-associated antigens, high doses of soluble anti-
gens, and now immune complexes. This suggests that in
this DC subset the MHC class I–restricted ‘cross-presenta-
tion pathway’ is constitutive for exogenous antigens and
does not depend on additional activating stimuli. The na-
ture of the transport system that shuttles antigens from the
endosome to the cytosol, which has been shown to be
present in DCs and not in macrophages, remains to be
identified (28).
Our data suggest that the activation state of CD8  DCs
is essential for the cross-presentation capacity of this DC
subset. The activation state of DCs is also crucial for the
functional outcome of the T cell–DC interaction. Non-
activated DCs tolerize or delete T cells, whereas activation
converts the DC to a stimulatory state that results in T cell
activation and memory (51). We hypothesize that CD8 
DCs constitutively cross-present exogenous antigens in the
context of MHC class I molecules and, in the absence of a
DC activation stimulus, this will tolerize CD8  T cells. As
CD8  DCs are more efficient in the presentation of exog-
Figure 7. Proliferation of OVA-specific CD8  T cells in vivo after
priming with OVA-IC is comparable in B6, Fc -chain–deficient mice
and Fc R-deficient mice. CFSE-labeled, Thy1.1  OT-I cells were trans-
ferred into B6, Fc -chain–deficient, and Fc R-deficient mice. 3 d later,
mice were primed by injection of OVA-IC. Spleen cells were isolated 3 d
after priming and stained for Thy1.1 and CD8. (A) CFSE profiles of
Thy1.1 CD8  OT-1 cells from mice that received no priming. (B) Same
profiles from mice that were primed with OVA-IC.825 den Haan and Bevan
enous antigens in the context of MHC class II, these cells
may be similarly involved in the tolerization of CD4  T
cells. We think that activation of both types of DCs will
enable them to activate T cells. CD8  DCs may still
mainly activate CD8  T cells, whereas activated CD8 
DCs may activate both CD8  and CD4  T cells. Activa-
tion of DCs can occur via activated CD4  T cells (52–54),
by interaction of pattern recognition receptors on the DC
with their ligands (55), or possibly via interaction of im-
mune complexes with activating Fc R (26). The in vivo
proliferation of OVA-specific CD8  T cells was not af-
fected in Fc R-deficient mice compared with wild-type
(Fig. 7). However, this short-term assay does not distin-
guish the eventual induction of T cell tolerance versus acti-
vation and memory, as both are preceded by proliferation
(56, 57). CD8  T cell activation after immune complex
priming has recently been shown to be CD4  T cell inde-
pendent, which suggests that interaction of immune com-
plexes with activating Fc Rs is sufficient for DC activation
(50, and unpublished data). Our model predicts that im-
mune complex priming in the absence of both CD4  T
cells and Fc Rs will result in tolerization, but this remains
to be investigated.
In addition to differences in cross-presentation of anti-
gens in the context of MHC class I, the two DC subsets
clearly differed in their capacity to present OVA-IC to
CD4  T cells: CD8  DCs were far superior in stimulating
OVA-specific CD4  T cells compared with CD8  DCs.
This is in line with the presentation of soluble OVA to
CD4  T cells by DC subsets, in which the CD8  DCs also
showed reduced CD4  T cell stimulating capacity com-
pared with the CD8  DC subset (24).
Autoantibodies and immune complexes are detected in
many autoimmune diseases. Deposition of these immune
complexes initiates inflammatory reactions leading to tis-
sue damage. In addition to these well known directly de-
structive effects of immune complexes, our data indicate
that immune complexes are also highly efficiently cross-
presented by DCs in vivo to both CD4  and CD8  T
cells. This in turn may result in activated autoantigen spe-
cific CD8  T cells that may contribute to tissue destruc-
tion. Both autoantibodies and CD8  T cells are present
and possibly involved in the development of diabetes,
Hashimoto’s thyroiditis, and primary biliary cirrhosis (58–
60). Complexes of autoantibodies and the E2 component
of pyruvate dehydrogenase were shown to be efficiently
cross-presented by human DCs and expanded E2 pyruvate
dehydrogenase specific CD8  T cells from primary biliary
cirrhosis patients in vitro (60). In addition to immune
complexes, DCs have also been shown to phagocytose an-
tibody coated tumor cells effectively eliciting tumor-spe-
cific CD8  T cells in vitro (61). This suggests that in-
creased DC cross-presentation and CD8  T cell activation
may also play a role in the protective effect of therapeutic
antitumor antibodies. Our study demonstrates that in vivo
cross-presentation of immune complexes is differentially
regulated in the CD8  and CD8  DC subsets. Further
elucidation of the role of CD8  and CD8  DCs in the
cross-priming of MHC class I-restricted T cells will be es-
sential to develop therapeutic strategies for both autoim-
mune diseases and tumors.
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